Gain Therapeutics Inc (GANX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 09-2024 | 06-2024 | 03-2024 | 12-2023 | 09-2023 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -16,643 | -12,157 | -4,014 | -22,268 | -17,544 |
| Depreciation Amortization | 63 | 41 | 21 | 84 | 60 |
| Accounts payable and accrued liabilities | 333 | 2,187 | 704 | -694 | 334 |
| Other Working Capital | -870 | 1,466 | 417 | 442 | 1,574 |
| Other Operating Activity | 1,698 | -880 | -713 | 3,570 | 2,370 |
| Operating Cash Flow | $-15,419 | $-9,343 | $-3,587 | $-18,866 | $-13,206 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | -22 | -22 | N/A | -15 | -15 |
| Purchase Of Investment | N/A | N/A | N/A | -1,956 | -1,956 |
| Sale Of Investment | 5,043 | 5,043 | 3,019 | 12,194 | 9,053 |
| Investing Cash Flow | $5,021 | $5,021 | $3,019 | $10,223 | $7,081 |
| Cash Flows From Financing Activities | |||||
| Debt Repayment | -68 | -45 | -23 | -89 | -67 |
| Common Stock Issued | 11,048 | 10,216 | 158 | 12,730 | 3,147 |
| Other Financing Activity | -281 | -281 | -281 | 0 | 0 |
| Financing Cash Flow | $10,699 | $9,891 | $-146 | $12,641 | $3,081 |
| Exchange Rate Effect | -47 | -429 | -443 | 488 | 5 |
| Beginning Cash Position | 11,829 | 11,829 | 11,829 | 7,342 | 7,342 |
| End Cash Position | 12,083 | 16,968 | 10,673 | 11,829 | 4,304 |
| Net Cash Flow | $254 | $5,139 | $-1,156 | $4,487 | $-3,039 |
| Free Cash Flow | |||||
| Operating Cash Flow | -15,419 | -9,343 | -3,587 | -18,866 | -13,206 |
| Capital Expenditure | -22 | -22 | N/A | -15 | -15 |
| Free Cash Flow | -15,441 | -9,365 | -3,587 | -18,881 | -13,221 |